Za zgodą użytkownika stosujemy ograniczoną analitykę chroniącą prywatność, aby zrozumieć, które ścieżki badawcze działają. Nie używamy trackerów reklamowych ani nagrywania sesji. Ten wybór można zmienić w Preferencjach. Przeczytaj Politykę prywatności.
Quote this valuation with its source: Fair value, Potential value and the price at analysis.
FAQ
CLX — frequently asked questions
Is The Clorox Company overvalued?
In our latest published analysis dated 2026-09-20, CLX looks meaningfully undervalued. The price recorded at analysis is 83,1 USD versus our fair value of 105 USD; the high endpoint is presented separately as potential value of 186 USD. That implies roughly 26.1% upside to fair value at that date.
Our latest published report, analyzed 2026-09-20, gives CLX a fair value of 105 USD and a potential value of 186 USD. The conclusion is triangulated across multiple valuation models and weighted by reliability for The Clorox Company's archetype; it is a dated research output, not a live price.
Should I buy CLX now?
Our latest published rating for CLX, analyzed 2026-09-20, is Buy. The Clorox Company looks meaningfully undervalued at the analysis-date price of 83,1 USD versus fair value of 105 USD; potential value is 186 USD. This is research for educational purposes, not personalized investment advice.
What are the biggest risks for CLX?
The dedicated bear-case section in our report analyzed 2026-09-20 documents The Clorox Company's material risks, evidence, thresholds, and thesis-invalidation conditions. Scenario-specific explanations remain in that section so the report does not repeat or decontextualize them elsewhere.
What is CLX's rating?
Our latest published rating for CLX, analyzed 2026-09-20, is Buy, with a published moat assessment of 6.5/10 (Narrow). It reflects our fair value of 105 USD, the potential value of 186 USD, and the price recorded at analysis (83,1 USD).
Ten raport nie został jeszcze przetłumaczony. Odśwież za kilka minut, gdy kolejka tłumaczeń go przetworzy.
§1 Podsumowanie wykonawczeEN
Odpowiedź w 30 sekundBuy
Cena a wartość
Cena
$83.10
Wartość godziwa
$104.80
Wartość potencjalna
$185.52
Stan na
2026-09-18
Dlaczego to może zadziałać
Restoring retail distribution breadth and consumer volume following supply disruptions drives fiscal 2027 net sales toward consensus estimates of $7,630M, enabling fixed-cost absorption to lift operating margins toward the 18.80% industry benchmark and advancing equity value toward Fair value of $104.80.
Co zmieniłoby naszą ocenę
Reported fiscal 2027 net sales growth falls below 8.0% YoY over the next 12 months.
Clorox is rated a Buy as retail distribution recovery offers 26.1% upside to our Fair value of $104.80, balanced against elevated debt of $5,520M.4
We rate The Clorox Company a Buy, indicating that the shares offer an attractive entry point for investors seeking operational recovery.
On September 18, 2026, the report was prepared with the stock at $83.10. This price stands 26.1% below our Fair value of $104.80, with long-term potential reaching $185.52 if turnaround execution accelerates.4
The primary risk is that retail shelf-space recovery fails if store brands permanently displace Clorox products. If fiscal 2027 sales growth stalls below 8.0%, operating cash flow will drop, making it difficult to service $5,520M in debt.
The main reason the stock can outperform is that brand equity supports retail distribution replenishment. Rebuilding retail shipments is expected to lift sales toward $7,630M in fiscal 2027, restoring operating cash flow above $612M and driving per-share value toward Fair value.1,4
Rebuilding retail shipments after supply disruptions is projected to restore fiscal 2027 revenue by 13.55% to $7,630M.1,4
Defensive Brand Equity
A 42.32% gross profit margin reflects durable consumer brand pricing power above household peer averages.4
Rekomendacja domu
Buy: operational distribution recovery supports cash generation toward Fair value of $104.80, offsetting risks from elevated leverage and competitor promotions.4
Przegląd spółki
The Company operates through strategic business units (SBUs) which are organized into operating segments. Operating segments are then aggregated into four reportable segments: Health and Wellness, Household, Lifestyle and International. The Company's IGNITE strategy accelerates innovation in key areas of the business to drive growth and deliver value for all Company stakeholders. IGNITE focuses on four strategic choices aimed at fueling long-term, profitable growth; innovating consumer experiences; reimagining how the company and its people work; and continuously evolving the product portfolio. In addition, IGNITE's integrated approach to sustainability supports long-term value creation for the Company and its stakeholders.
•Health and Wellness consists of cleaning, disinfecting, sanitizing and professional products marketed and sold in the United States.
§2 Scenariusz negatywnyEN
In a severe operational stress test where volume restoration stalls and promotional concessions compress operating margins toward 12.0%, free cash flow drops below debt service requirements. With $5,520M in total debt and $602M in annual dividend commitments, post-dividend cash flow turns deeply negative, forcing credit rating downgrades and debt refinancing at elevated borrowing costs.
Competitive promotions and private label penetration restrict volume recovery, forcing retailer concessions that impair cash flow and elevate balance sheet refinancing strain.
Jak ta teza może się załamać
Turnaround Volume Restoration Failure
Retailers decline to restore pre-outage shelf space and private label substitution permanently displaces Clorox products, causing FY27 revenue rebound to miss minimum recovery threshold of 8.0% YoY.4
FV impact
-2.1%
Revenue and EPS growth 5 points lower for five years
Trigger
Within 12 months
Promotional Margin Collapse
Price wars and retailer concessions to defend volume against peers compress operating margin below 12.0%.
Sygnały wczesnego ostrzegania do monitorowania
Pięć zdarzeń, które osłabiłyby naszą tezę inwestycyjną.
01
Annual Net Sales Growth
Failure to rebound indicates permanent retail shelf-space loss to private label brands following distribution disruptions, impairing top-line recovery and fixed-cost absorption across domestic manufacturing facilities.
Alarm, jeśliReported FY2027 revenue growth below 8.0% YoY over next 12 months
02
§3 Przewaga konkurencyjnaEN
Narrow
Clorox possesses a Narrow economic moat grounded in brand intangible assets and scale distribution advantages across household cleaning categories. Its flagship brand commands consumer recognition, allowing the company to sustain a 42.32% gross margin, which exceeds peer averages such as Kimberly-Clark at 37.61%.
However, moat breadth remains narrow rather than wide due to intense competition from branded peers like Church & Dwight (operating margin 18.07%) and retail private label substitution. These competitive pressures constrain long-term pricing leverage and necessitate ongoing promotional spending to maintain retail shelf space.
Zysk ekonomiczny
Clorox generates economic profits through brand equity in domestic cleaning that commands consumer loyalty, though peer rivalry from Church & Dwight and Kimberly-Clark limits pricing power.
02Scale Distribution Cost Advantage — Scale distribution relationships across primary retail channels enable nationwide fulfillment and shelf presence across domestic cleaning aisles.
Znane zagrożenia dla przewagi
Zagrożenie
Powaga
Oś czasu
Złagodzenie
Retail Shelf Space Displacement by Private Label
medium
12 to 18 months
Increased marketing reinvestment and product innovation in core bleach and cleaning formulations.4
The highlighted cell is Fair value when every assumption sits at its base level ($104.80). Each row and column shows what Fair value becomes when one assumption moves.
FY2026 operating cash flow reached $612M with capital expenditures disciplined at $207M, generating $405M in free cash flow. However, annual dividend distributions of $602M exceed free cash flow, creating negative net cash after dividends and restricting organic debt reduction.4,5
Alokacja kapitału
Management curtailed share repurchases, recording negative buyback outflows of $256M in FY2026, while prioritizing dividend continuity and debt service on $5,520M in total debt.
Podsumowanie bilansuJak wykazane aktywa są utrzymywane i finansowane w wybranym okresie.
StockMarketAgent.AI
Struktura aktywówFinansowane przez
Aktywa ogółem7,8 mld USDŚrodki pieniężne143 mln USDAktywa obrotowe1,8 mld USDZobowiązania ogółem7,5 mld USDZobowiązania krótkoterminowe2,8 mld USDKapitał własny252 mln USD
Dane podziału bilansu
Aktywa ogółem
7 794 000 000 USD
Środki pieniężne
143 000 000 USD
Aktywa obrotowe
1 824 000 000 USD
Zobowiązania ogółem
7 542 000 000 USD
Zobowiązania krótkoterminowe
2 773 000 000 USD
Kapitał własny
252 000 000 USD
Most przepływów pieniężnychJak przepływy operacyjne przełożyły się na wolne przepływy pieniężne w FY2026.
StockMarketAgent.AI
Uzgodnienie przepływów operacyjnych
Zysk netto587 mln USDAmortyzacja+247 mln USDWynagrodzenie w akcjach+48 mln USDPozostałe korekty operacyjne−270 mln USDOperacyjne przepływy pieniężne612 mln USD
Uzgodnienie środków na początek i koniec
Środki pieniężne na początek170 mln USDOperacyjne przepływy pieniężne+612 mln USDPrzepływy inwestycyjne−2,3 mld USDPrzepływy finansowe+1,7 mld USDWpływ kursów walutowych−2 mln USDŚrodki pieniężne na koniec143 mln USD
612 mln USD − 207 mln USDWolne przepływy pieniężne 405 mln USD
Dane mostu przepływów pieniężnych
Zysk netto
587 000 000 USD
Wpływy operacyjne
882 000 000 USD
Amortyzacja
247 000 000 USD
Wynagrodzenie w akcjach
48 000 000 USD
Operacyjne przepływy pieniężne
612 000 000 USD
Wydatki operacyjne
270 000 000 USD
Dostępne środki pieniężne
2 450 000 000 USD
Środki pieniężne na początek
170 000 000 USD
Wpływy finansowe
1 668 000 000 USD
Wydatki inwestycyjne
2 301 000 000 USD
Capex
207 000 000 USD
Pozostała działalność inwestycyjna
2 094 000 000 USD
Wpływ kursów walutowych
2 000 000 USD
Środki pieniężne na koniec
143 000 000 USD
Przepływy inwestycyjne
-2 301 000 000 USD
Przepływy finansowe
1 668 000 000 USD
Przychody i wynikiJak skala działalności przekłada się na raportowany zysk.
Gotówka i zadłużenieDostępna płynność wobec całkowitego zadłużenia.
Generowanie gotówkiPrzepływy operacyjne w porównaniu z wolnymi przepływami pieniężnymi.
RentownośćZmiany marży brutto, operacyjnej i netto.
Dane finansowe na określony moment użyte w analizie z 2026-09-20.
Dane historii finansowej
Okres
Przychody
EBITDA
Zysk netto
Operacyjne przepływy pieniężne
Wolne przepływy pieniężne
Capex
Amortyzacja
Wynagrodzenie w akcjach
Skup akcji
Wypłacone dywidendy
Emisja długu netto
Przepływy inwestycyjne
Przepływy finansowe
Środki pieniężne na początek
Środki pieniężne na koniec
Gotówka i inwestycje
Zadłużenie ogółem
Marża operacyjna
ROIC
WACC
Spread ROIC−WACC
2017-06-30
6 mld USD
1,3 mld USD
701 mln USD
865 mln USD
634 mln USD
231 mln USD
163 mln USD
51 mln USD
183 mln USD
412 mln USD
—
-205 mln USD
-645 mln USD
—
419 mln USD
419 mln USD
1,8 mld USD
18,7%
—
4,5%
—
2018-06-30
—
1,3 mld USD
823 mln USD
976 mln USD
782 mln USD
194 mln USD
166 mln USD
53 mln USD
271 mln USD
450 mln USD
—
-859 mln USD
-399 mln USD
419 mln USD
134 mln USD
131 mln USD
2,3 mld USD
—
—
4,8%
—
2019-06-30
6,2 mld USD
1,3 mld USD
820 mln USD
992 mln USD
786 mln USD
206 mln USD
180 mln USD
43 mln USD
661 mln USD
490 mln USD
—
-196 mln USD
-815 mln USD
134 mln USD
113 mln USD
111 mln USD
2,3 mld USD
17,8%
—
3,9%
—
2020-06-30
6,7 mld USD
1,5 mld USD
939 mln USD
1,5 mld USD
1,3 mld USD
254 mln USD
180 mln USD
50 mln USD
248 mln USD
533 mln USD
—
-252 mln USD
-523 mln USD
113 mln USD
879 mln USD
871 mln USD
2,8 mld USD
18,8%
—
2,2%
—
2021-06-30
7,3 mld USD
1,2 mld USD
710 mln USD
1,3 mld USD
945 mln USD
331 mln USD
211 mln USD
50 mln USD
905 mln USD
558 mln USD
—
-452 mln USD
-1,4 mld USD
879 mln USD
324 mln USD
319 mln USD
2,8 mld USD
16,7%
—
2,8%
—
2022-06-30
7,1 mld USD
937 mln USD
462 mln USD
786 mln USD
535 mln USD
251 mln USD
224 mln USD
52 mln USD
25 mln USD
571 mln USD
-83 mln USD
-229 mln USD
-689 mln USD
324 mln USD
186 mln USD
183 mln USD
2,5 mld USD
10,1%
—
4,3%
—
2023-06-30
7,4 mld USD
564 mln USD
149 mln USD
1,2 mld USD
930 mln USD
228 mln USD
236 mln USD
73 mln USD
0 USD
583 mln USD
-188 mln USD
-223 mln USD
-753 mln USD
186 mln USD
368 mln USD
367 mln USD
2,5 mld USD
11,1%
—
5,3%
—
2024-06-30
7,1 mld USD
723 mln USD
280 mln USD
695 mln USD
483 mln USD
212 mln USD
235 mln USD
74 mln USD
0 USD
595 mln USD
-45 mln USD
-175 mln USD
-655 mln USD
368 mln USD
207 mln USD
202 mln USD
2,5 mld USD
10,2%
—
6,1%
—
2025-06-30
7,1 mld USD
1,4 mld USD
810 mln USD
981 mln USD
761 mln USD
220 mln USD
219 mln USD
81 mln USD
332 mln USD
602 mln USD
0 USD
-94 mln USD
-924 mln USD
207 mln USD
170 mln USD
167 mln USD
2,5 mld USD
16,6%
—
6,4%
—
2026-06-30
6,7 mld USD
921 mln USD
587 mln USD
612 mln USD
405 mln USD
207 mln USD
247 mln USD
48 mln USD
256 mln USD
602 mln USD
2,6 mld USD
-2,3 mld USD
1,7 mld USD
170 mln USD
143 mln USD
143 mln USD
5,5 mld USD
24,7%
—
—
—
§9 Porównanie wyceny z konkurentami
Wartość godziwaReport-date price
The Clorox CompanyCLX
Cena / wartość godziwa
Wartość godziwa104,8 USDReport-date price83,1 USD
Data oceny
Przewaga konkurencyjnaNarrow
Karta wyników inwestycyjnych53 / 100
The J.M. Smucker CompanySJM
Cena / wartość godziwa
Wartość godziwa81,01 USDReport-date price120,02 USD
The Clorox Company (CLX) trades at 14.2x forward earnings against a peer median of 18.3x. Its EV/EBITDA of 13.7x compares with a peer median of 13.5x. The comparison uses 4 peers: The J.M. Smucker Company, Church & Dwight Co. Inc., Kimberly-Clark Corporation and The Estee Lauder Companies Inc., as of 2026-09-20.
§10 Branża i cyklEN
Faza cyklu
Contraction
Industry capital expenditures to depreciation stand at 1.07 and capex to revenue is 1.1%, reflecting disciplined maintenance spending rather than aggressive manufacturing capacity additions across consumer defensive peers.
Cykl byczy
Demand expansion accelerates as consumer staple volume recovers across retail grocery channels, enabling branded producers to protect gross margins above 45%.
Cykl niedźwiedzi
Persistent consumer trade-down to private label forces defensive promotional concessions, keeping operating margins near 13.7% and limiting organic growth.
E-Commerce and Omnichannel Household Replenishment
positive
Subscription delivery models and digital re-ordering favor established national brands with high customer loyalty.
Post-Pandemic Health and Disinfection Habits
positive
Sustained household and institutional sanitation standards maintain baseline demand for core cleaning products.
Pozycjonowanie
Clorox maintains leading market share in domestic bleach and cleaning categories, but must balance trade promotions against peers Church & Dwight and Kimberly-Clark while repairing supply chain relationships.
§11 Zarządzanie pozycjąEN
Wielkość pozycji
3-5%
Moderate position sizing reflects operational turnaround execution potential balanced against elevated leverage of $5,520M debt.4
Ryzyko
Portfolio risk is managed through disciplined stop-loss execution and position sizing caps to insulate capital against leverage and competitive headwinds.
Transze wejścia
Poziom
Działanie
Dlaczego
$83.10
Initiate primary tranche
Report-date price of $83.10 offers a 26.1% discount to Fair value of $104.80.
$78.00-$80.00
Add secondary tranche
Provides enhanced margin of safety if broader market volatility compresses consumer defensive multiples.
The shares trade at a 26.1% discount to Fair value of $104.80, supported by $612M in operating cash flow and resilient brand equity.4
Turnaround Operational Perspective
Buy
Shipment recovery across retail partners is projected to lift fiscal 2027 revenue by 13.55% to $7,630M, driving operational normalization.1
Balance Sheet and Income Perspective
Buy
Maintain a disciplined 3% to 5% allocation while monitoring debt service on $5,520M debt against operating cash generation.4
§14 Końcowa rekomendacjaEN
Działanie
Kupuj
We recommend a Buy on The Clorox Company based on operational recovery restoring distribution and driving revenue toward $7,630M in fiscal 2027.1
At $83.10, the stock trades at an attractive 26.1% discount to Fair value of $104.80, with robust underlying cash conversion of $612M operating cash flow supporting debt service.
§15Your notes
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
Private notes
Visible only to you. Synced to this device.
0 chars
Sources
The records this analysis drew on, as they stood when it was run.
Market and peer researchData as of 2026-09-20 · Published 2026-09-20 · Provider-adjusted · cited for 2 figuresCited in Przewaga konkurencyjna, Branża i cykl
Not every cited input appears here: internal calculations and intermediate model outputs have no external record, and some citations could not be matched to one.
Inability to deleverage against $5,520M total debt forces refinancing at wider credit spreads, elevating borrowing costs and pushing cost of capital above 8.58%.2,4
Intense promotional concessions to defend market share against Church & Dwight erode core profitability, reducing operating earnings and preventing the business from funding necessary marketing reinvestment.
Diminished cash generation leaves insufficient liquidity to cover capital expenditures and dividend commitments, stalling debt paydown and forcing reliance on additional external borrowing.
Persistent commodity input inflation combined with unrecovered retail pricing power compresses product margins, demonstrating that branded equity is failing to command consumer price premiums over private store alternatives.
Turnaround execution outpaces expectations as consumer loyalty drives retail shelf replenishment and margin expansion toward Potential value of $185.52.
Dlaczego to ważne
Margin expansion toward peer levels demonstrates brand pricing power and promotional discipline.